• Annual Meeting
  • News
  • Donate
  • Contact
  • HSG Clinical Trials & Research
    • About Clinical Trials
    • Current HSG Trials
      • PROOF-HD
        • PROOF-HD: Study Locations
        • PROOF-HD: FAQs
      • KINECT-HD2
      • KINECT-HD
        • KINECT-HD: Study Locations
        • KINECT-HD: FAQs
        • KINECT-HD: About HD
        • KINECT-HD: About Clinical Studies
    • Past HSG Research Trials & Studies
    • HSG Credentialed Sites
    • Contact Me About Future Research
  • myHDstory™
  • HSG Credentialing & Membership
    • Get Credentialed for HD Research
    • Become a HSG Member
      • HSG Membership Application
      • Membership Profile Update
  • Education & Care
    • CME4HD – Accredited Learning
    • HD Care Education Videos
    • HD Care and Treatment Resources
    • HD Care Improvement Project
    • Disclaimer of Medical Advice
  • Other HSG Resources
    • UHDRS® – Unified Huntington’s Disease Rating Scale
      • UHDRS® Request Form
    • HD Insights
      • Periodical (e-version)
      • HD Insights Podcast
    • Publications
  • Living with HD
    • HD Basics
    • HD Quiz: Myths & Facts
    • HD Drug Pipeline
    • I AM THE DIFFERENCE!
  • About HSG
    • What is the HSG?
    • Our Services
      • Scientific Advisory Council
    • Our Accomplishments
    • Our Organization
    • Our Annual Meeting
      • HSG 2023
      • Past Annual Meetings
    • Careers

SIGNAL completes enrollment in cohort A

Share This

vaccinex_logoVaccinex Inc. completed enrollment of cohort A in its SIGNAL Clinical Trial, a randomized Phase 2 study to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503 in subjects at risk for or with early signs of Huntington’s Disease. Read the press release.

  • Clinical Trial
  • Enrollment
  • SIGNAL
  • trial participation
Previous Post
Teva Press Release: April 24, 2014
News, Press Releases
Next Post
FDA Requests More Data on Potential New Treatment for Huntington Disease
News, Press Releases

Related Posts

Huntington Study Group Announces Call for Abstracts for the 30th Annual Meeting
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington’s Disease in The Lancet Neurology 
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington’s Disease in The Lancet Neurology 
Huntington Study Group Achieves Last Patient Last Visit for Its Observational Study to Test Virtual Use of the Unified Huntington’s Disease Rating Scale®
HSG and HD-CAB Collaborate to Provide Global Patient Advisory Board
  • Quick Links

    Find a HSG Trial or Study
    Get Credentialed for HD Research
    Accredited Training on HD (CME4HD)
    HSG Annual Meeting
    UHDRS®
    Disclaimer of Medical Advice
    HSG Code of Conduct

  • Applications + Forms

    HSG Member Application
    Member Update Submission
    Investigator Application
    Coordinator Application
    New Site Application
    Site Letter of Agreement 
    UHDRS® Request Form
    Future Research Contact Form

  • Contact HSG

    Huntington Study Group
    95 Allens Creek Road
    Building 1, Suite 132
    Rochester, NY 14618, USA

    Toll Free (North America): 800-487-7671
    Fax: 585-672-9912

    Email: info@hsglimited.org

                    

Copyright © 2023 Huntington Study Group. All Rights Reserved. | Privacy Statement | Terms of Use | Financial Disclosures